Clinical trials: Hepatocellular Carcinoma Resectable
Resectable Hepatocellular Carcinoma
Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer
This phase II trial studies the effect of nivolumab and ADI-PEG 20 before surgery in treating patients with liver cancer that can be removed by surgery (resectable).
- Trial name
- NCT04965714
- Testing
- Nivolumab, Pegargiminase, Resection
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Hepatoma Resectable
The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
It is a prospective, non-randomized, single-arm cohort study. A total of 10 patients will be included in this study. Based on standardized treatment, the treatment of bioartificial liver device will be applied 48-72 hours after…
- Trial name
- NCT05035108
- Testing
- hiHep bioartificial liver therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sir Run Run Shaw Hospital
Liver Carcinoma Resectable
Trans-parenchymal Compressing Suture in Major Liver Resection
Non-anatomical liver resection with appropriate resection margin was regarded as a potential curative treatment for selected major hepatic carcinoma due to preserving maximal normal liver, especially in cirrhotic patients.
- Trial name
- NCT03215290
- Testing
- TCS
- Volunteers
- 382 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC
The aim of this study is to collect data on efficacy and tolerability on a large series of patient of different Italian hospitals in order to support the validation of LifePearl with robust and consistent clinical evidence.
- Trial name
- LIFDOX (NCT03734068)
- Testing
- Chemoembolization Using LifePearl, Doxorubicin
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Hepatocellular Carcinoma (HCC)
HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC
This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC).
- Trial name
- HCC-MPDS (NCT07700082)
- Where
- China
- Volunteers
- 555 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma Non-resectable
TACE Combined With Lenvatinib and Sintilimab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599790
- Testing
- TACE combined with lenvatinib and sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Non-resectable
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
This study is conducted to evaluate the efficacy and safety of lenvatinib plus sintilimab, transarterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE) and hepatic artery infusion chemotherapy (HAIC) with FOLFOX…
- Trial name
- NCT06904183
- Testing
- LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
This pilot clinical trial studies stereotactic body radiation therapy in treating patients with liver cancer that cannot be removed by surgery.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01899261
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Montefiore Medical Center
Hepatocellular Carcinoma Non-resectable
SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC
This multicenter retrospective study evaluated the efficacy and safety of selective internal radiation therapy (SIRT) combined with lenvatinib and PD-(L)1 inhibitors (SIRT-L-P) versus transarterial chemoembolization (TACE)…
- Trial name
- NCT06916546
- Testing
- SIRT-L-P, TACE-L-P
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma Resectable
A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin
This is a prospective, single-arm, single-center, clinical research.This trial will explore the efficacy and safety of Camrelizumab in combination with Apatinib Mesylate and Oxaliplatin for neoadjuvant therapy in patients with…
- Trial name
- NCT04850040
- Testing
- Apatinib Mesylate, Camrelizumab, Oxaliplatin
- Volunteers
- 15 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Liver Cancer
DX-8951f in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have liver cancer.
- Trial name
- NCT00004108
- Testing
- exatecan mesylate
- Where
- 4 sites in United States
- Sponsor
- Daiichi Sankyo
Liver Cancer
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01009801
- Testing
- doxorubicin-eluting beads, everolimus
- Where
- 8 sites in Switzerland
- Volunteers
- 27 people
- Sponsor
- Swiss Cancer Institute
Hepatocellular Carcinoma Non-resectable, HCC
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
A Phase II study of immunotherapy with Durvalumab (MEDI4736) and Tremelimumab in combination with Y-90 SIRT for intermediate stage HCC
- Trial name
- IMMUWIN (NCT04522544)
- Testing
- Tremelimumab, Durvalumab, Y-90 SIRT
- Where
- 11 sites in Germany
- Volunteers
- 55 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable
Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma
The aim of this prospective, randomized study is to compare TRA vs TFA for superselective embolization of HCC using bland microparticles performed by multiple operators. In particular, main objectives are to compare: 1.
- Trial name
- NCT03807947
- Testing
- Radial TAE - Bland embolization with 40-100 Microparticles, Transfemoral TAE - Bland embolization with 40-100 Microparticles
- Where
- Italy
- Volunteers
- 74 people
- Sponsor
- Humanitas Clinical and Research Center
Hepatocellular Carcinoma
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
This study is an open-label, single-arm prospective clinical trial that evaluates the efficacy and safety of neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib in the treatment of…
- Trial name
- NCT06349317
- Testing
- Neoadjuvant intensity-modulated radiotherapy combined with perioperative camrelizumab and apatinib
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Yongyi Zeng
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma, Neoadjuvant Therapy
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
Surgical resection is the preferred therapeutic modality for patients with resectable hepatocellular carcinoma (HCC). However, the recurrence rate of HCC remains up to 70%.
- Conditions
- Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
- Trial name
- NCT07324824
- Testing
- sintilimab combined with bevacizumab biosimilar
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-sen University
Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor
An Exploratory Study of Single-Dose Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable HCC
The goal of this clinical trial is to evaluate whether giving a single dose of Nivolumab (Opdivo®) before curative surgery for patients with resectable liver cancer can activate the body's immune response against the cancer and…
- Conditions
- Hepato Cellular Carcinoma (HCC), Immune Checkpoint Inhibitor, Neoadjuvant Therapy
- Trial name
- NCT07902258
- Testing
- Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital